Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Citi
UBS
Express Scripts
US Department of Justice
Chubb
Harvard Business School
Baxter
Mallinckrodt

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 074826

« Back to Dashboard

NDA 074826 describes ESTAZOLAM, which is a drug marketed by Mayne Pharma, Par Pharm, and Watson Labs, and is included in three NDAs. It is available from three suppliers. Additional details are available on the ESTAZOLAM profile page.

The generic ingredient in ESTAZOLAM is estazolam. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the estazolam profile page.
Summary for 074826
Tradename:ESTAZOLAM
Applicant:Par Pharm
Ingredient:estazolam
Patents:0
Formulation / Manufacturing:see details
Medical Subject Heading (MeSH) Categories for 074826

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength1MG
Approval Date:Jul 3, 1997TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength2MG
Approval Date:Jul 3, 1997TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Federal Trade Commission
Healthtrust
Covington
Baxter
Deloitte
Daiichi Sankyo
Harvard Business School
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.